How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Deoxyribonucleic Acid (DNA) Vaccines Market
- By Vaccine Type: Plasmid DNA Vaccines, Linear DNA Vaccines, Minicircle DNA Vaccines, Doggybone DNA Vaccines
- By Target Disease: Infectious Diseases, Cancer, Autoimmune Diseases, Allergic Diseases
- By Delivery Method: Intramuscular Injection, Intradermal Injection, Electroporation, Gene Gun Delivery
- By End User: Hospitals, Research Laboratories, Biotechnology Companies, Contract Research Organizations (CROs)
- By Technology Platform: Non-viral Vectors, Viral Vectors, Nanoparticle-based Delivery, Lipid-based Delivery Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Plasmid DNA Vaccines leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Deoxyribonucleic Acid (DNA) Vaccines Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 4
Target Disease 4
Delivery Method 4
End User 4
Technology Platform 4
Companies profiled
Inovio Pharmaceuticals Inc.
Zydus Cadila
AnGes Inc.
Genexine Inc.
Vaxart Inc.
Osivax
Applied DNA Sciences Inc.
Immunomic Therapeutics Inc.
Entos Pharmaceuticals Inc.
Agenus Inc.
CureVac N.V.
Dynavax Technologies Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Inovio Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Zydus Cadila
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AnGes Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Genexine Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Vaxart Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Osivax
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Applied DNA Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Immunomic Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Entos Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Agenus Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CureVac N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Dynavax Technologies Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Vical Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GeneOne Life Science Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Takis Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,361M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Plasmid DNA Vaccines42.4
- Linear DNA Vaccines20.0
- Minicircle DNA Vaccines17.4
- Doggybone DNA Vaccines20.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$952.1M → $2,151M · 10.7%
Europe$663.6M → $1,403M · 9.8%
Asia Pacific$605.9M → $1,449M · 11.5%
Latin America$375.1M → $901.0M · 11.6%
Middle East and Africa$288.5M → $637.6M · 10.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.342026
10.362027
10.362028
10.372029
10.382030
10.402031
10.412032
10.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Inovio Pharmaceuticals Inc.18.8
- Zydus Cadila11.9
- AnGes Inc.11.0
- Genexine Inc.6.8
- Vaxart Inc.11.8
- Osivax11.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type29.1%
Target Disease10.8%
Delivery Method19.6%
End User15.5%
Technology Platform25.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe21.5
- Asia Pacific22.2
- Latin America13.8
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals Inc. | 90 | 75 | 80 | 98 | 85 | 95 | 87 |
| Zydus Cadila | 75 | 80 | 88 | 90 | 81 | 69 | 81 |
| AnGes Inc. | 62 | 82 | 66 | 67 | 74 | 81 | 72 |
| Genexine Inc. | 72 | 68 | 72 | 73 | 57 | 81 | 71 |
| Vaxart Inc. | 58 | 58 | 60 | 57 | 57 | 55 | 58 |
| Osivax | 58 | 67 | 70 | 63 | 55 | 64 | 63 |
| Applied DNA Sciences Inc. | 45 | 47 | 58 | 51 | 58 | 65 | 54 |
| Immunomic Therapeutics Inc. | 60 | 49 | 58 | 59 | 57 | 43 | 54 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Inovio Pharmaceuticals Inc.
- Zydus Cadila
- AnGes Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals Inc. | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Zydus Cadila | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| AnGes Inc. | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Genexine Inc. | ◐ | ✓ | ◐ | ◐ | − | ◐ |
| Vaxart Inc. | ◐ | ◐ | − | ◐ | − | ◐ |
| Osivax | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Applied DNA Sciences Inc. | − | − | ◐ | − | − | ◐ |
| Immunomic Therapeutics Inc. | ◐ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Inovio Pharmaceuticals Inc.87
2Zydus Cadila81
3AnGes Inc.72
4Genexine Inc.71
5Osivax63
6Vaxart Inc.58
7Applied DNA Sciences Inc.54
8Immunomic Therapeutics Inc.54
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Inovio Pharmaceuticals Inc.Zydus Cadila
Challenger2
Strong scale, closing on the leaders.
AnGes Inc.Genexine Inc.
Contender2
Focused players with pockets of strength.
Vaxart Inc.Osivax
Niche2
Specialists in a single segment or region.
Applied DNA Sciences Inc.Immunomic Therapeutics Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Deoxyribonucleic Acid (DNA) Vaccines Market — a $238M beachhead inside a $3.86B market.
Beachhead (SOM)$238Mobtainable near-term
Serviceable (SAM)$1.43Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Plasmid DNA Vaccines
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer76 fit
Linear DNA Vaccines
Strong fit — clear ROI and a fast path to value.
End user66 fit
Minicircle DNA Vaccines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Disease & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Delivery Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel30%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Deoxyribonucleic Acid (DNA) Vaccines Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation15%
Closed-won5%
$21.0KCAC
$81KLTV
3.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Deoxyribonucleic Acid (DNA) Vaccines Market is a durable-growth opportunity — $5.45B by 2033, compounding at 7.2%.
TAM · 2025$3.12Btoday
TAM · 2033$5.45Bforecast
CAGR7.2%2027–2033
Cumulative$37.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.45BTotal addressable market
SAM$1.96BServiceable available market
SOM$382MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.45BLarge & growingTAM by 2033 at 7.2% CAGR
$1.96BServiceable nowreachable with today’s model
$382MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.25BBear4.7% CAGR
$5.45BBase7.2% CAGR
$6.98BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Disease optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Deoxyribonucleic Acid (DNA) Vaccines Market — a $3.72B market by 2033. Plan: grow share from 7.6% to 14.6%.
Market size · 2033$3.72Btotal addressable
Market CAGR6.3%2027–2033
Target share14.6%from 7.6% today
Revenue ambition$543Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 14.6% | Ahead |
| Revenue | $293M | $543M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 29.6% | 42.0% | At risk |
| Customer retention | 90.0% | 93.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Disease capability
A defensible second engine — invest in Target Disease to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Disease
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $64M capacity & capability investment
- Greenlight bolt-on M&A in Target Disease
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Deoxyribonucleic Acid (DNA) Vaccines Market conversation — a $3.75B market you can size, segment and defend in minutes.
Market size · 2033$3.75Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers1,733+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 3 mopayback period
$50K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Inovio Pharmaceuticals Inc.Zydus CadilaAnGes Inc.Genexine Inc.Vaxart Inc.OsivaxApplied DNA Sciences Inc.Immunomic Therapeutics Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Deoxyribonucleic Acid (DNA) Vaccines Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Deoxyribonucleic Acid (DNA) Vaccines Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Department Of Gynaecology And Obstetrics Forceps Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportDepartmental Picture Archiving and Communication System (PACS) Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportD-Ephedrine hydrochloride CAS 24221-86-1 Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportDEPi (Di-ethyl Phosphite) and DMPi (Di-methyl Phosphite) Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportDEPi (Di-ethyl Phosphite) Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportDepilatories (Skincare) Market
Market size, share, segmentation and regional forecast.
$412M market · 2025 base year
View reportDepilatory Creams Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportDeployable Military Shelters Market
Market size, share, segmentation and regional forecast.
$490M market · 2025 base year
View reportDeployable Roll Over Protection Systems (ROPS) Market
Market size, share, segmentation and regional forecast.
$749M market · 2025 base year
View reportDeployable Tactical Cables Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportDepolarizers Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportDeposit Control Additives Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.